Skip the spoonful of sugar, Banner Pharmacaps uses gelatin to help the medicine go down. The company develops and makes a range of softgels for convenient oral dosage and delivery of prescription, over-the-counter (OTC), and nutritional medicines and supplements. Its soft gelatin technologies are used in both branded and private-label OTC products, such as pain and cold medicines. Banner also works with prescription drugmakers to enhance solubility and delivery methods for existing products, as well as for compounds in clinical trial stages. It specializes in softgel technologies that control release rate and enhance performance of certain compounds. Parent company VION has agreed to sell Banner to Patheon.
Contract manufacturing firm Patheon will pay some $255 million to acquire Banner Pharmacaps, with the goal of expanding its oral dosage development and manufacturing operations.
Banner Pharmacaps has manufacturing facilities in the US, Canada, Mexico, and the Netherlands. Banner Pharmacaps also maintains research and development operations in the four countries where it has manufacturing plants, with its primary R&D center located in North Carolina. North Carolina is also the site of its corporate headquarters and a state-of-the-art production facility. Banner's European plant manufactures softgels and Soflet Gelcaps, while its facility in Mexico sells finished packaged products directly to consumers under the Pharmacaps and Gelcaps brands.
Banner Pharmacaps' scientists are experienced in the field of oral drug delivery and work to develop softgel variations often in conjunction with major pharmaceutical companies. For instance, in 2011 the company formed an alliance with Impax Laboratories to develop softgel capsule products
▲ Show Less▼ Show Full Description